Our work demonstrated for the first time that both SOD1+/A272C and FUS+/G1566A mutations are able to be corrected by CRISPR/Cas9-mediated gene editing technique in ALS patient specific iPSCs. Here, FUS is linked to amyotrophic lateral sclerosis.